Bone Biologics Corp - 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held on June 1, 2016. The filing was submitted on June 2, 2016, by Bone Biologics Corporation, a Delaware corporation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
Stockholders voted on four proposals at the Annual Meeting. The results were as follows:
- Proposal I (Election of Directors): Approved. Stephen LaNeve, Bruce Stroever, Dr. Chia Soo, William Coffin, John Booth, Jimmy Delshad, and Dr. Benjamin Wu were elected. Votes: 36,582,773 FOR, 0 WITHHELD, 1,505,715 NON VOTES.
- Proposal II (Executive Compensation): Approved on an advisory basis. Votes: 36,582,773 FOR, 0 AGAINST, 0 ABSTAIN.
- Proposal III (Frequency of Compensation Vote): Stockholders voted for an annual frequency. Votes: 22,468,775 for one year, 11,642,804 for two years, 2,471,194 for three years, 0 ABSTAIN.
- Proposal IV (Ratification of Auditors): Approved. Anton & Chia, LLP was ratified as the independent registered public accountant for the fiscal year ending December 31, 2016. Votes: 36,582,773 FOR, 0 AGAINST, 0 ABSTAIN.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items beyond the standard disclosure of the meeting results.
Key Facts for Investor Verification
- Verify the definitive proxy statement filed on May 6, 2016, for detailed background on the director nominees and executive compensation.
- Confirm the appointment of Anton & Chia, LLP as the independent auditor for the 2016 fiscal year.
- Note that the majority of voting stock supported an annual advisory vote on executive compensation.